Management of hypoparathyroidism: Summary statement and guidelines

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 6, 2016, Pages 2273-2283

  Brandi, Maria Luisa ^a   Bilezikian, John P ^b   Shoback, Dolores ^c   Bouillon, Roger ^d   Clarke, Bart L ^e   Thakker, Rajesh V ^f   Khan, Aliya A ^g   Potts, John T ^h  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Columbia University College of Physicians ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g MCMASTER UNIVERSITY   (Canada)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; RECOMBINANT PARATHYROID HORMONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE DENSITY; CLINICAL EVALUATION; CLINICAL FEATURE; CONFERENCE PAPER; DRUG SAFETY; HORMONE DETERMINATION; HUMAN; HYPERCALCIURIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPARATHYROIDISM; MANAGED CARE; MEDICAL HISTORY; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SUPPLEMENTATION; TREATMENT OUTCOME; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE;

DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; HYPOPARATHYROIDISM;

EID: 84973562918     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3907     Document Type: Conference Paper

References (90)

1. Stack BC Jr, Bimston DN, Bodenner DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: postoperative hypoparathyroidism-definitions and management. Endocr Pract. 2015;21:674-685.
2. Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology clinical guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173:G1-G20.
3. Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005;187:311-325.
4. Brown EM. PTH secretion in vivo and in vitro. Regulation by calcium and other secretagogues. Miner Electrolyte Metab. 1982;8: 130-150.
5. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
6. Clarke BL, Brown EM, Collins MT, et al. Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab. 2016;101: 2282-2299.
7. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: Etiologies and clinical features [published online March 4, 2016]. J Clin Endocrinol Metab. 2016;101:2300-2312.
8. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359:391-403.
9. Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med. 1984; 310:1221-1225.
10. Ferrè S, Hoenderop JJ, Bindels RJ. Role of the distal convoluted tubule in renal Mg2-handling: molecular lessons from inherited hypomagnesemia. Magnes Res. 2011;24:S101-S108.
11. Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med. 1983;309:873-877.
12. Ghosh L, Shah M, Pate S, Mannari J, Sharma K. Wilson's disease presenting with hypokalemia, hypoparathyroidism and renal failure. J Assoc Physicians India. 2012;60:57-59.
13. Fatima J, Karoli R, Jain V. Hypoparathyroidism in a case of Wilson's disease: Rare association of a rare disorder. Indian J Endocrinol Metab. 2013;17:361-362.
14. Horwitz CA, Myers WP, Foote FW Jr. Secondary malignant tumors of the parathyroid glands. Report of two cases with associated hypoparathyroidism. Am J Med. 1972;52:797-808.
15. Watanabe T, Adachi I, Kimura S, et al. A case of advanced breast cancer associated with hypocalcemia. Jpn J Clin Oncol. 1983;13: 441-448.
16. Thakker RV, Bringhurst FR, Juppner H. Genetic disorders of calcium homeostasis caused by abnormal regulation of parathyroid hormone secretion or responsiveness. In: DeGroot LJ, Jameson JL, eds. Endocrinology. Philadelphia, PA: W.B. Saunders Company; 2016:1063-1089.
17. Hannan FM, Thakker RV. Investigating hypocalcaemia. BMJ. 2013;346:f2213.
18. Lee S, Mannstadt M, Guo J, et al.Ahomozygous [Cys25]PTH(1-84) mutation that impairs PTH/PTHrP receptor activation defines a novel form of hypoparathyroidism. J Bone Miner Res. 2015;30: 1803-1813.
19. Powers J, Joy K, Ruscio A, Lagast H. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28:2570-2576.
20. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Cardiovascular and renal complications to postsurgical hypoparathyroidism: A Danish nationwide controlled historic follow-up study. J Bone Miner Res. 2013;28:2277-2285.
21. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Miner Res. 2014;29:2504-2510.
22. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L. The epidemiology of nonsurgical hypoparathyroidism in Denmark: A nationwide case finding study. J Bone Miner Res. 2015;30:1738-1744.
23. Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidectomy: A prospective study. Arch Surg. 2008;143:132-137; discussion 138. 24.
24. Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336:1298-1302.
25. Bastepe M. Genetics and epigenetics of parathyroid hormone resistance. Endocr Dev. 2013;24:11-24.
26. Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes. 2012;19:443-451.
27. Bastepe M, Jüppner H. Pseudohypoparathyroidism, Albright's hereditary osteodystrophy, and progressive osseous heteroplasia: disorders caused by inactivating GNAS mutations. In: DeGroot LJ, Jameson JL, eds. Endocrinology. Philadelphia, PA: W.B. Saunders Company; 2016:1147-1159.
28. Mantovani G. Clinical review: pseudohypoparathyroidism: diagnosis and treatment. J Clin Endocrinol Metab. 2011;96:3020-3030.
29. Akin L, Kurtoǧ lu S, Yildiz A, Akin MA, Kendirici M. Vitamin D deficiency rickets mimicking pseudohypoparathyroidism. J Clin Res Pediatr Endocrinol. 2010;2:173-175.
30. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:391-399.
31. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3570-3579.
32. D'Amour P. Acute and chronic regulation of circulating PTH: Significance in health and in disease. Clin Biochem. 2012;45:964-969.
33. De Sanctis V, Soliman A, Fiscina B. Hypoparathyroidism: From diagnosis to treatment. Curr Opin Endocrinol Diabetes Obes. 2012; 19:435-442.
34. Goswami R, Millo T, Mishra S, et al. Expression of osteogenic molecules in the caudate nucleus and gray matter and their potential relevance for basal ganglia calcification in hypoparathyroidism. J Clin Endocrinol Metab. 2014;99:1741-1748.
35. Srirangarajan S, Satyanarayan A, Ravindra S, Thakur S. Dental manifestation of primary idiopathic hypoparathyroidism. J Indian Soc Periodontol. 2014;18:524-526.
36. Mannstadt MM, Mitchell DM. Clinical manifestations of hypoparathyroidism. In: Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT Jr, eds. The Parathyroids. London: Academic Press 2015;761-770.
37. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23:2018-2024.
38. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L, Hypoparathyroid Study Group. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358-2370.
39. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1-84): A prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137-144.
40. Chen Q, Kaji H, Iu MF, et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 2003;88:4655-4658.
41. Rubin MR, Dempster DW, Kohler T, et al. Three dimensional cancellous bone structure in hypoparathyroidism. Bone. 2010;46:190-195.
42. Cusano NE, Nishiyama KK, Zhang C, et al. Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J Bone Miner Res. 2016;31:308-316.
43. Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:2727-2736.
44. Dempster D. Bone histomorphometry in hypoparathyroidism. In: Brandi ML, Brown EM, eds. Hypoparathyroidism. New York, NY: Springer 2015;287-296.
45. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996;18:103-108.
46. Mendonça ML, Pereira FA, Nogueira-Barbosa MH, et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord. 2013;13:1.
47. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97:4507-4514.
48. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002; 146:215-222.
49. Cho NL, Moalem J, Chen L, Lubitz CC, Moore FD, Ruan DT. Surgeons and patients disagree on the potential consequences from hypoparathyroidism. Endocr Pract. 2014;20:427-446.
50. Aggarwal S, Kailash S, Sagar R, et al. Neuropsychological dysfunction in idiopathic hypoparathyroidism and its relationship with intracranial calcification and serum total calcium. Eur J Endocrinol. 2013;168:895-903.
51. Hadker N, Egan J, Sanders J, Lagast H, Clarke BL. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study. Endocr Pract. 2014;20:671-679.
52. Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99:3694-3699.
53. Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: Results from a randomized controlled trial. Osteoporos Int. 2014;25:1717-1726.
54. Santonati A, Palermo A, Maddaloni E, et al. PTH(1-34) for surgical hypoparathyroidism: A prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2015;100:3590-3597.
55. Holt EH, Bilezikian JP. Calcium disorders. In: McKean SC, Ross JJ, Dressler DD, Brotman DJ, Ginsberg JS, eds. Principles and Practice of Hospital Medicine. New York, NY: McGraw Hill; 2012;2067-2076.
56. Schafer AL, Shoback D. Hypocalcemia: definition, etiology, pathogenesis, diagnosis, and management. In: Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed. American Society of Bone and Mineral Research. Hoboken, NJ: Wiley-Blackwell; 2013;572-578.
57. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am. 1993;22:363-375.
58. Ballane GT, Sfeir JG, Dakik HA, Brown EM, El-Hajj Fuleihan G. Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy. Eur J Endocrinol. 2012;166:1113-1120.
59. Castellano KL, Plantalech LC. Post surgical hypoparathyroidism (HP): Treatment with teriparatide (TP). Bone. 2006;38:S7.
60. Puig-Domingo M, Díaz G, Nicolau J, Fernández C, Rueda S, Halperin I. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. Eur J Endocrinol. 2008;159:653-657.
61. Mahajan A, Narayanan M, Jaffers G, Concepcion L. Hypoparathyroidism associated with severe mineral bone disease postrenal transplantation, treated successfully with recombinant PTH. Hemodial Int. 2009;13:547-550.
62. Heaney RP, Dowell MS, Bierman J, Hale CA, Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr. 2001;20:239-246.
63. Harvey JA, Zobitz MM, Pak CY. Dose dependency of calcium absorption: A comparison of calcium carbonate and calcium citrate. J Bone Miner Res. 1988;3:253-258.
64. Milman S, Epstein EJ. Protonpumpinhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocr Pract. 2011; 17:104-107.
65. Subbiah V, Tayek JA. Tetany secondary to the use of a proton-pump inhibitor. Ann Intern Med. 2002;137:219.
66. Zaya NE, Woodson G. Proton pump inhibitor suppression of calcium absorption presenting as respiratory distress in a patient with bilateral laryngeal paralysis and hypocalcemia. Ear Nose Throat J. 2010;89:78-80.
67. Russell RG, Smith R, Walton RJ, et al. 1, 25-dihydroxycholecalciferol and 1-α hydroxycholecalciferol in hypoparathyroidism. Lancet. 1974;2:14-17.
68. Kooh SW, Fraser D, DeLuca HF, et al. Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: Evidence for impaired conversion of 25-hydroxyvitaminDto 1 α, 25-dihydroxyvitamin D. N Engl J Med. 1975;293:840-844.
69. Neer RM, Holick MF, DeLuca HF, Potts JT Jr. Effects of 1 αhydroxy-vitamin D3 and 1, 25-dihydroxy-vitamin D3 on calcium and phosphorus metabolism in hypoparathyroidism. Metabolism. 1975;24:1403-1413.
70. Mortensen L, Hyldstrup L, Charles P. Effect of vitamin Dtreatment in hypoparathyroid patients: A study on calcium, phosphate and magnesium homeostasis. Eur J Endocrinol. 1997;136:52-60.
71. Haussler MR, Cordy PE. Metabolites and analogues of vitamin D. Which for what? JAMA. 1982;247:841-844.
72. Halabe A, Arie R, Mimran D, Samuel R, Liberman UA. Hypoparathyroidism-A long-term follow-up experience with 1 α vitamin D3 therapy. Clin Endocrinol (Oxf). 1994;40:303-307.
73. Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf). 2012;77:200-206.
74. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry. J Clin Densitom. 2013;16:455-466.
75. Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98:2356-2361.
76. Natpara [package insert]. Bedminster, NJ; NPS Pharmaceuticals, Inc; 2015.
77. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276:631-636.
78. Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:3480-3486.
79. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:4214-4220.
80. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetichumanparathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:2680-2688.
81. Winer KK, Fulton KA, Albert PS, Cutler GB Jr. Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr. 2014;165:556-563.
82. Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: An open-label, single-dose, phase I study. Clin Ther. 2014;36:722-736.
83. Wang H, Liu J, Yin Y, et al. Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment. PLoS One. 2014;9:e88237.
84. Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28:2232-2243.
85. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1:275-283.
86. Gafni RI, Guthrie LC, Kelly MH, et al. Transient increased calcium and calcitriol requirements after discontinuation ofhumansynthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism. J Bone Miner Res. 2015;30(11):2112-2118.
87. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321.
88. Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol. 2006;34:929-940.
89. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Miner Res. 2012; 27:2429-2437.
90. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: A decade of experience. J Bone Miner Res. 2012;27:2419-2428.